Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 10/2022

21.10.2022 | Demyelinating Disorders (L. Wooliscroft and D. Bourdette, Section Editors)

An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis

verfasst von: Marwa Kaisey, Ghazal Lashgari, Justyna Fert-Bober, Daniel Ontaneda, Andrew J. Solomon, Nancy L. Sicotte

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

For many patients, the multiple sclerosis (MS) diagnostic process can be lengthy, costly, and fraught with error. Recent research aims to address the unmet need for an accurate and simple diagnostic process through discovery of novel diagnostic biomarkers. This review summarizes recent studies on MS diagnostic fluid biomarkers, with a focus on blood biomarkers, and includes discussion of technical limitations and practical applicability.

Recent Findings

This line of research is in its early days. Accurate and easily obtainable biomarkers for MS have not yet been identified and validated, but several approaches to uncover them are underway.

Summary

Continue efforts to define laboratory diagnostic biomarkers are likely to play an increasingly important role in defining MS at the earliest stages, leading to better long-term clinical outcomes.
Literatur
1.
Freedman MS, et al. Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. Mult Scler Relat Disord. 2014;3(2):147–55.PubMedCrossRef
2.
Solomon AJ, Corboy JR. The tension between early diagnosis and misdiagnosis of multiple sclerosis. Nat Rev Neurol. 2017;13(9):567–72.PubMedCrossRef
3.
4.
Kaisey M, et al. Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers. Mult Scler Relat Disord. 2019;30:51–6.PubMedCrossRef
5.
Kelly SB, et al. Multiple sclerosis, from referral to confirmed diagnosis: an audit of clinical practice. Mult Scler J. 2011;17(8):1017–21.CrossRef
6.
Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73.PubMedCrossRef
7.
Masjuan J, Alvarez-Cermeno JC, Garcia-Barragan N, Diaz-Sanchez M, Espino M, Sadaba MC, et al. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology. 2006;66(4):576e8.CrossRef
8.
Tricco AC, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467–73.PubMedCrossRef
9.
Novakova L, et al. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem. 2017;141(2):296–304.PubMedCrossRef
10.
11.
Edwards KR, et al. Neurofilament light chain as an indicator of exacerbation prior to clinical symptoms in multiple sclerosis. Mult Scler Relat Disord. 2019;31:59–61.PubMedCrossRef
12.
13.
14.
15.
Teunissen CE, et al. Combination of CSF <em>N</em>-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009;72(15):1322.PubMedCrossRef
16.
17.
Olesen MN, et al. Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study. J Neuroinflammation. 2019;16(1):59.PubMedPubMedCentralCrossRef
18.
Bjornevik K, et al. Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. JAMA Neurol. 2020;77(1):58–64.PubMedCrossRef
19.
Bjornevik K, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296–301.PubMedCrossRef
20.
Schneider R, et al. Plasma Neurofilament light levels are increased in people with Radiologically Isolated Syndrome (P1–1.Virtual). Neurology. 2022;98(18 Supplement):2084.
21.
Matute-Blanch C, et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain. 2018;141(4):1085–93.PubMedCrossRef
22.
Bridel C, et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol. 2019;76(9):1035–48.PubMedPubMedCentralCrossRef
23.
Eng LF, et al. An acidic protein isolated from fibrous astrocytes. Brain Res. 1971;28(2):351–4.PubMedCrossRef
24.
Probert F, et al. Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands. Front Immunol. 2022;12.
25.
Högel H, et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler J. 2018;26(2):210–9.CrossRef
26.
27.
Niiranen M, et al. Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021;56:103280.PubMedCrossRef
28.
Sun M, et al. A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta- analysis. Mult Scler Relat Disord. 2021;51:102870.PubMedCrossRef
29.
Momtazmanesh S, et al. Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. Rev Neurosci. 2021;32(6):573–95.PubMedCrossRef
30.
Abdelhak A, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18(3):158–72.PubMedCrossRef
31.
Bracco F, et al. Free light chains in the CSF in multiple sclerosis. J Neurol. 1987;234(5):303–7.PubMedCrossRef
32.
Kricka LJ, Park JY. Assay Principles in Clinical Pathology. In: McManus LM, Mitchell RN, editors. Pathobiology of Human Disease. San Diego: Academic Press; 2014. p. 3207–21.CrossRef
33.
Leurs CE, et al. Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Mult Scler J. 2019;26(8):912–23.CrossRef
34.
Gaetani L, et al. Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. J Neuroimmunol. 2020;339:577108.PubMedCrossRef
35.
Altinier S, et al. Free light chains in cerebrospinal fluid of multiple sclerosis patients negative for IgG oligoclonal bands. Clin Chim Acta. 2019;496:117–20.PubMedCrossRef
36.
Christiansen M, et al. Cerebrospinal fluid free kappa light chains and kappa index perform equal to oligoclonal bands in the diagnosis of multiple sclerosis. Clin Chem Lab Med. 2018;57(2):210–20.PubMedCrossRef
37.
Gurtner KM, et al. CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. Clin Chem Lab Med. 2018;56(7):1071–80.PubMedCrossRef
38.
39.
Sanz Diaz CT, et al. Evaluation of Kappa Index as a Tool in the Diagnosis of Multiple Sclerosis: Implementation in Routine Screening Procedure. Front Neurol. 2021;12:676527–676527.PubMedPubMedCentralCrossRef
40.
Crespi I, et al. Combined use of Kappa Free Light Chain Index and Isoelectrofocusing of Cerebro-Spinal Fluid in Diagnosing Multiple Sclerosis: Performances and Costs. Clin Lab. 2017;63(3):551–9.PubMed
41.
Cavalla P, et al. Kappa free light chains index in the differential diagnosis of Multiple Sclerosis from Neuromyelitis optica spectrum disorders and other immune-mediated central nervous system disorders. J Neuroimmunol. 2020;339:577122.PubMedCrossRef
42.
Konen FF, et al. The Increasing Role of Kappa Free Light Chains in the Diagnosis of Multiple Sclerosis. Cells. 2021;10(11):3056.
43.••
Saadeh RS, et al. CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis. Mayo Clin Proc. 2022;97(4):738–51. Along with NfL, this is the MS biomarker most likely to be clinically relevant to readers now and is available as a commercial test.PubMedCrossRef
44.
Saadeh R, et al. CSF kappa Free Light Chains as a Potential Quantitative Alternative to Oligoclonal Bands in Multiple Sclerosis (S37. 001). 2019, AAN Enterprises.
45.
Konen FF, et al. The Impact of Immunomodulatory Treatment on Kappa Free Light Chains as Biomarker in Neuroinflammation. Cells. 2020;9(4):842.
46.
Lotan I, et al. Saliva immunoglobulin free light chain analysis for monitoring disease activity and response to treatment in multiple sclerosis. Mult Scler Relat Disord. 2020;44:102339.PubMedCrossRef
47.
Kouchaki E, et al. Correlation of Serum Levels of IL-33, IL-37, Soluble Form of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), and Circulatory Frequency of VEGFR2- expressing Cells with Multiple Sclerosis Severity. Iran J Allergy Asthma Immunol. 2017;16(4):329–37.PubMed
48.
Mado H, et al. Plasma Interleukin-33 level in relapsing-remitting multiple sclerosis. Is it negatively correlated with central nervous system lesions in patients with mild disability? Clin Neurol Neurosurg. 2021;206:106700.PubMedCrossRef
49.
Alsahebfosoul F, et al. Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis. Biomol Concepts. 2017;8(1):55–60.PubMedCrossRef
50.
Mishima R, et al. High Plasma Osteopontin Levels in Patients With Inflammatory Bowel Disease. J Clin Gastroenterol. 2007;41(2):167–172.
51.
52.
Agah E, et al. Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis. PLoS One. 2018;13(1):e0190252.PubMedPubMedCentralCrossRef
53.
Golabi M, et al. Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients. Inflammation, 2022;45(4):1815–1828.
54.
Rabenstein M, et al. Osteopontin directly modulates cytokine expression of primary microglia and increases their survival. J Neuroimmunol. 2016;299:130–8.PubMedCrossRef
55.
Orsi G, et al. Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light. Mult Scler Relat Disord. 2021;51:102923.PubMedCrossRef
56.
Kariya Y, et al. Increased cerebrospinal fluid osteopontin levels and its involvement in macrophage infiltration in neuromyelitis optica. BBA clinical. 2015;3:126–34.PubMedPubMedCentralCrossRef
57.
Han RK, et al. Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barré syndrome. J Clin Immunol. 2014;34(1):94–103.PubMedCrossRef
58.
Olsson B, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–84.PubMedCrossRef
59.
60.
61.
Cantó E, et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain. 2015;138(4):918–31.PubMedCrossRef
62.
Hinsinger G, et al. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler J. 2015;21(10):1251–61.CrossRef
63.
Comabella M, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain. 2010;133(4):1082–93.PubMedCrossRef
64.
Borràs E, et al. Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis. Mol Cell Proteomics. 2016;15(1):318–28.PubMedCrossRef
65.
Kušnierová P, et al. Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases. PLoS One. 2020;15(5):e0233519.PubMedPubMedCentralCrossRef
66.
Mañé-Martínez MA, et al. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. J Neuroimmunol. 2016;299:112–7.PubMedCrossRef
67.
Keene CD, et al. Luminex-based quantification of Alzheimer’s disease neuropathologic change in formalin-fixed post-mortem human brain tissue. Lab Invest. 2019;99(7):1056–67.PubMedCrossRef
68.
De Fino C, et al. The predictive value of CSF multiple assay in multiple sclerosis: A single center experience. Mult Scler Relat Disord. 2019;35:176–81.PubMedCrossRef
69.
Comabella M, et al. CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1082.
70.
71.
72.
D'Anca M, et al. Extracellular Vesicles in Multiple Sclerosis: Role in the Pathogenesis and Potential Usefulness as Biomarkers and Therapeutic Tools. Cells. 2021;10(7):1733.
73.
Doeuvre L, et al. Cell-derived microparticles: a new challenge in neuroscience. J Neurochem. 2009;110(2):457–68.PubMedCrossRef
74.
Jia L, et al. Blood neuro-exosomal synaptic proteins predict Alzheimer’s disease atthe asymptomatic stage. Alzheimers Dement. 2021;17(1):49–60.PubMedCrossRef
75.
Turpin D, et al. Role of extracellular vesicles in autoimmune diseases. Autoimmun Rev. 2016;15(2):174–83.PubMedCrossRef
76.
Barreca MM, Aliotta E, Geraci F. Extracellular Vesicles in Multiple Sclerosis as Possible Biomarkers: Dream or Reality? Adv Exp Med Biol. 2017;958:1–9.PubMedCrossRef
77.
Pieragostino D, et al. Enhanced release of acid sphingomyelinase-enriched exosomes generates a lipidomics signature in CSF of Multiple Sclerosis patients. Sci Rep. 2018;8(1):3071.PubMedPubMedCentralCrossRef
78.
Moyano AL, et al. Sulfatides in extracellular vesicles isolated from plasma of multiple sclerosis patients. J Neurosci Res. 2016;94(12):1579–87.PubMedCrossRef
79.
Galazka G, et al. Multiple sclerosis: Serum-derived exosomes express myelin proteins. Mult Scler. 2018;24(4):449–58.PubMedCrossRef
80.
Pieragostino D, et al. Proteomics characterization of extracellular vesicles sorted by flow cytometry reveals a disease-specific molecular cross-talk from cerebrospinal fluid and tears in multiple sclerosis. J Proteomics. 2019;204:103403.PubMedCrossRef
81.
Dalla Costa G, et al. CSF extracellular vesicles and risk of disease activity after a first demyelinating event. Mult Scler J. 2021;27(10):1606-1610:1352458520987542.
82.
Verderio C, et al. Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol. 2012;72(4):610–24.PubMedCrossRef
83.
Laso-García F, et al. Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis. PLoS One. 2018;13(9):e0202590.PubMedPubMedCentralCrossRef
84.
85.
Brickshawana A, et al. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol. 2014;13(8):795–806.PubMedPubMedCentralCrossRef
86.
Nerrant E, et al. Lack of confirmation of anti-inward rectifying potassium channel4.1 antibodies as reliable markers of multiple sclerosis. Mult Scler J. 2014;20(13):1699–703.CrossRef
87.
Brill L, et al. Increased anti-KIR4.1 antibodies in multiple sclerosis: Could it be a marker of disease relapse? Mult Scler J. 2014;21(5):572–9.CrossRef
88.
Pröbstel AK, et al. Multiple Sclerosis and Antibodies against KIR4.1. N Engl J Med. 2016;374(15):1496–8.PubMedCrossRef
89.
90.
Marnetto F, et al. Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients. J Immunol Methods. 2017;445:53–8.PubMedCrossRef
91.
Navas-Madroñal M, et al. Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review. Plos One. 2017;12(4):e0175538.PubMedPubMedCentralCrossRef
92.
Marino M, et al. Low reliability of anti-KIR4.1(83–120) peptide auto-antibodies in multiple sclerosis patients. Mult Scler. 2018;24(7):910–8.PubMedCrossRef
93.
94.
Maggi P, et al. Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. Ann Neurol. 2020;88(5):1034–42.PubMedCrossRef
95.
96.
Bergsland N, et al. Serum iron concentration is associated with subcortical deep gray matter iron levels in multiple sclerosis patients. NeuroReport. 2017;28(11):645–8.PubMedCrossRef
97.
Al-Radaideh A, El-Haj N, Hijjawi N. Iron deposition and atrophy in cerebralgrey matter and their possible association with serum iron in relapsing-remitting multiple sclerosis. Clin Imaging. 2021;69:238–42.PubMedCrossRef
98.
Magliozzi R, et al. Iron homeostasis, complement, and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis. Ann Clin Transl Neurol. 2019;6(11):2150–63.PubMedPubMedCentralCrossRef
99.
Starčević Čizmarević N, et al. Lack of association between C282Y and H63D polymorphisms in the hemochromatosis gene and risk of multiple sclerosis: A meta- analysis. Biomed Rep. 2022;16(2):12–12.PubMedCrossRef
100.
Trentini A, et al. Evaluation of total, ceruloplasmin-associated and type IIferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci. 2017;377:133–6.PubMedCrossRef
101.
Nirooei E, et al. Blood Trace Element Status in Multiple Sclerosis: a Systematic Review and Meta-analysis. Biol Trace Elem Res. 2022;200(1):13–26.PubMedCrossRef
102.
103.
Munger KL, et al. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler. 2011;17(10):1185–93.PubMedPubMedCentralCrossRef
104.
Kieff EaR, A.B., Fields Virology. Lippincott Williams & Wilkins; 2001. p. 2511–2573. Philadelphia, PA, USA
105.
Gieß RM, et al. Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis. PLoS One. 2017;12(4):e0175279.PubMedPubMedCentralCrossRef
106.
Sisay S, et al. Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS. J Neuroimmunol. 2017;306:40–5.PubMedCrossRef
107.
108.
Ha GE, et al. The Ca2+-activated chloride channel anoctamin-2 mediates spike- frequency adaptation and regulates sensory transmission in thalamocortical neurons. Nat Commun. 2016;7(1):13791.PubMedPubMedCentralCrossRef
109.
110.••
Tengvall K, et al. Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. Proc Natl Acad Sci U S A. 2019;116(34):16955–60. This paper both addresses a test with a lot of current interest (EBNA) and shows that it may be a specific marker for MS, distinguishing it from clinically relevant mimics, when combined with another marker (ANO2).PubMedPubMedCentralCrossRef
111.
Lampert P, Carpenter S. ELECTRON MICROSCOPIC STUDIES ON THE VASCULAR PERMEABILITY AND THE MECHANISM OF DEMYELINATION IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS. J Neuropathol Exp Neurol. 1965;24:11–24.PubMedCrossRef
112.
Gay D, Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain. 1991;114(Pt 1B):557–72.PubMedCrossRef
113.
Lucchinetti CF, et al. Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis. Brain Pathol. 1996;6(3):259–74.PubMedCrossRef
114.
Sati P, et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol. 2016;12(12):714–22.PubMedCrossRef
115.
Ontaneda D, et al. Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS- MS) study protocol for a prospective multicenter trial. NeuroImage Clin. 2021;32:102834.PubMedPubMedCentralCrossRef
116.
Kalinowska-Łyszczarz A, et al. Serum sPECAM-1 and sVCAM-1 levels are associated with conversion to multiple sclerosis in patients with optic neuritis. J Neuroimmunol. 2016;300:11–4.PubMedCrossRef
117.
Jasiak-Zatońska M, et al. Different blood-brain-barrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus. Neurol Neurochir Pol. 2022;56(3):246–255.
118.
Rocha NP, et al. Exploring the relationship between Endothelin-1 andperipheral inflammation in multiple sclerosis. J Neuroimmunol. 2019;326:45–8.PubMedCrossRef
119.
Monti L, Arrigucci U, Rossi A. Insights into Endothelin-3 and Multiple Sclerosis. Biomol Concepts. 2020;11(1):137–41.PubMedCrossRef
120.
Yun JW, et al. Neurolymphatic biomarkers of brain endothelial inflammatory activation: Implications for multiple sclerosis diagnosis. Life Sci. 2019;229:116–23.PubMedCrossRef
121.
Zinger A, et al. Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients. Mult Scler J. 2016;22(14):1883–7.CrossRef
122.
Olsson A, et al. Circulating levels of tight junction proteins in multiple sclerosis: Association with inflammation and disease activity before and after disease modifying therapy. Mult Scler Relat Disord. 2021;54:103136.PubMedCrossRef
123.
Akil E, et al. Serum endocan levels in multiple sclerosis relapse and remission. Eur Rev Med Pharmacol Sci. 2021;25(11):4091–8.PubMed
124.
Cirac A, et al. The Aryl Hydrocarbon Receptor-Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1043.PubMedPubMedCentralCrossRef
125.
Mazzucco M, et al. CNS endothelial derived extracellular vesicles are biomarkers of active disease in multiple sclerosis. Fluids Barriers CNS. 2022;19(1):13.PubMedPubMedCentralCrossRef
126.
Wu R, et al. MicroRNA-448 promotes multiple sclerosis development throughinduction of Th17 response through targeting protein tyrosine phosphatase non-receptor type 2 (PTPN2). Biochem Biophys Res Commun. 2017;486(3):759–66.PubMedCrossRef
127.
Paraboschi EM, et al. Genetic association and altered gene expression of mir-155 in multiple sclerosis patients. Int J Mol Sci. 2011;12(12):8695–712.PubMedPubMedCentralCrossRef
128.
Zhang J, et al. MicroRNA-155 modulates Th1 and Th17 cell differentiation and is associated with multiple sclerosis and experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014;266(1–2):56–63.PubMedCrossRef
129.
Ahmed Ali M, et al. Relationship between miR-155 and miR-146a polymorphisms and susceptibility to multiple sclerosis in an Egyptian cohort. Biomed Rep. 2020;12(5):276–84.PubMedPubMedCentral
130.
Mameli G, et al. Natalizumab Therapy Modulates miR-155, miR-26a and Proinflammatory Cytokine Expression in MS Patients. PLoS One. 2016;11(6):e0157153.PubMedPubMedCentralCrossRef
131.
Arruda LC, et al. Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients. Bone Marrow Transplant. 2015;50(3):380–9.PubMedCrossRef
132.
Michell-Robinson MA, et al. Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis. Ann Clin Transl Neurol. 2016;3(1):27–41.PubMedCrossRef
133.
Saridas F, et al. The expression and prognostic value of miR-146a and miR-155 in Turkish patients with multiple sclerosis. Neurol Res. 2021;44(3):1–7.
134.
Regev K, et al. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e267.PubMedPubMedCentralCrossRef
135.
Lücking CB, et al. Association between Early-Onset Parkinson’s Disease and Mutations in the Parkin Gene. N Engl J Med. 2000;342(21):1560–7.PubMedCrossRef
136.
Joodi Khanghah O, et al. Evaluation of the Diagnostic and Predictive Value of Serum Levels of ANT1, ATG5, and Parkin in Multiple Sclerosis. Clin Neurol Neurosurg. 2020;197: 106197.PubMedCrossRef
137.
Hassanpour M, et al. The relationship between ANT1 and NFL with autophagy and mitophagy markers in patients with multiple sclerosis. J Clin Neurosci. 2020;78:307–12.PubMedCrossRef
138.••
Cossu D, et al. Potential of PINK1 and PARKIN Proteins as Biomarkers for Active Multiple Sclerosis: A Japanese Cohort Study. Front Immunol. 2021;12: 681386. This study highlights a novel group of biomarkers not commonly considered related to MS and how they may distinguish MS from common mimics including other neuroimmune diseases.PubMedPubMedCentralCrossRef
139.
Tahani S, et al. Elevated serum level of IL-4 in neuromyelitis optica and multiple sclerosis patients. J Immunoassay Immunochem. 2019;40(5):555–63.PubMedCrossRef
140.
Levraut M, et al. Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities. Front Immunol. 2022;13:1–12.
141.
Matejčíková Z, et al. Cerebrospinal fluid and serum levels of interleukin-8 in patients with multiple sclerosis and its correlation with Q-albumin. Mult Scler Relat Disord. 2017;14:12–5.PubMedCrossRef
142.
Sedeeq MS, et al. Micro-RNA-96 and interleukin-10 are independent biomarkers for multiple sclerosis activity. J Neurol Sci. 2019;403:92–6.PubMedCrossRef
143.
Olesen MN, et al. Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study. J Neuroinflammation. 2019;16(1):59.PubMedPubMedCentralCrossRef
144.
Li M, et al. Identification and Clinical Validation of Key Extracellular Proteins as the Potential Biomarkers in Relapsing-Remitting Multiple Sclerosis. Front Immunol. 2021;12.
145.
Naderi S, et al. IL-27 plasma level in relapsing remitting multiple sclerosis subjects: The double-faced cytokine. J Immunoassay Immunochem. 2016;37(6):659–70.PubMedCrossRef
146.
Eslami M, et al. Serum levels and genetic variation of IL-35 are associated with multiple sclerosis: a population-based case-control study. Immunol Res. 2022;70(1):75–85.PubMedCrossRef
147.
Alsahebfosoul F, et al. Serum level of interleukin 36 in patients with multiple sclerosis. J Immunoassay Immunochem. 2018;39(5):558–64.PubMedCrossRef
148.
Zarrabi M, et al. Elevated IL-38 Serum Levels in Newly Diagnosed Multiple Sclerosis and Systemic Sclerosis Patients. Med Princ Pract. 2021;30(2):146–53.PubMedCrossRef
149.
Badihian S, et al. Decreased serum levels of interleukin-35 among multiple sclerosis patients may be related to disease progression. J Biol Regul Homeost Agents. 2018;32(5):1249–53.PubMed
150.
151.
Bhargava P, et al. Altered Levels of Toll-Like Receptors in Circulating Extracellular Vesicles in Multiple Sclerosis. Cells. 2019;8(9):1058.
152.
Welton JL, et al. Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis. J Extracell Vesicles. 2017;6(1):1369805.PubMedPubMedCentralCrossRef
153.
Geraci F, et al. Differences in Intercellular Communication During Clinical Relapse and Gadolinium-Enhanced MRI in Patients With Relapsing Remitting Multiple Sclerosis: A Study of the Composition of Extracellular Vesicles in Cerebrospinal Fluid. Front Cell Neurosci. 2018;12:418.PubMedPubMedCentralCrossRef
154.
Bhargava P, et al. Synaptic and complement markers in extracellular vesicles in multiple sclerosis. Mult Scler. 2021;27(4):509–18.PubMedCrossRef
155.
Qu X, et al. MiR-30a inhibits Th17 differentiation and demyelination of EAE mice by targeting the IL-21R. Brain Behav Immun. 2016;57:193–9.PubMedCrossRef
156.
Mahmoudian E, et al. Thioredoxin-1, redox factor-1 and thioredoxin-interacting protein, mRNAs are differentially expressed in Multiple Sclerosis patients exposed and non-exposed to interferon and immunosuppressive treatments. Gene. 2017;634:29–36.PubMedCrossRef
157.
158.
Ehya F, et al. Identification of miR-24 and miR-137 as novel candidate multiple sclerosis miRNA biomarkers using multi-staged data analysis protocol. Mol Biol Res Commun. 2017;6(3):127–40.PubMedPubMedCentral
159.
Pahlevan Kakhki M, et al. HOTAIR but not ANRIL long non-coding RNA contributes to the pathogenesis of multiple sclerosis. Immunology. 2018;153(4):479–87.PubMedCrossRef
160.
Gharesouran J, et al. A Novel Regulatory Function of Long Non-coding RNAs at Different Levels of Gene Expression in Multiple Sclerosis. J Mol Neurosci. 2019;67(3):434–40.PubMedCrossRef
161.
Gharesouran J, et al. Integrative analysis of OIP5-AS1/HUR1 to discover new potential biomarkers and therapeutic targets in multiple sclerosis. J Cell Physiol. 2019;234(10):17351–60.PubMedCrossRef
162.
Azimi M, et al. Altered Expression of miR-326 in T Cell-derived Exosomes of Patients with Relapsing-remitting Multiple Sclerosis. Iran J Allergy Asthma Immunol. 2019;18(1):108–13.PubMed
163.
Talebian S, et al. Assessment of expression of RELN signaling pathway in multiple sclerosis patients. Immunobiology. 2019;224(3):402–7.PubMedCrossRef
164.
Salek Esfahani B, et al. Down-regulation of ERMN expression in relapsing remitting multiple sclerosis. Metab Brain Dis. 2019;34(5):1261–6.PubMedCrossRef
165.
Elkhodiry AA, Zamzam DA, El Tayebi HM. miR-155 and functional proteins of CD8+ T cells as potential prognostic biomarkers for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021;53:103078.PubMedCrossRef
166.
Shaker OG, et al. LncRNAs, MALAT1 and lnc-DC as potential biomarkers for multiple sclerosis diagnosis. Biosci Rep. 2019;39(1):BSR20181335.
167.
Mohamed DAW, et al. Apoptotic protease activating factor-1 gene and MicroRNA- 484: A possible interplay in relapsing remitting multiple sclerosis. Mult Scler Relat Disord. 2022;58:103502.PubMedCrossRef
168.
Vistbakka J, et al. Circulating microRNAs as biomarkers in progressive multiple sclerosis. Mult Scler. 2017;23(3):403–12.PubMedCrossRef
169.
Vistbakka J, et al. Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR- 376c–3 in multiple sclerosis patients. Acta Neurol Scand. 2018;138(2):130–6.PubMedCrossRef
170.
Ahmadian-Elmi M, et al. miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4+ T lymphocytes of patients with relapsing-remitting multiple sclerosis. Immunogenetics. 2016;68(1):43–54.PubMedCrossRef
171.
Guan H, et al. Inverse correlation of expression of microRNA-140-5p with progression of multiple sclerosis and differentiation of encephalitogenic T helper type 1 cells. Immunology. 2016;147(4):488–98.PubMedPubMedCentralCrossRef
172.
Golabi M, et al. Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing-Remitting Multiple Sclerosis Patients. Inflammation. 2022:1815–1828.
173.
Rahimirad S, et al. Identification of hsa-miR-106a-5p as an impact agent on promotion of multiple sclerosis using multi-step data analysis. Neurol Sci. 2021;42(9):3791–9.PubMedCrossRef
174.
175.
Quintana E, et al. miRNAs in cerebrospinal fluid identify patients with MS and specifically those with lipid-specific oligoclonal IgM bands. Mult Scler. 2017;23(13):1716–26.PubMedCrossRef
176.
Wan C, et al. MicroRNA 182 promotes T helper 1 cell by repressing hypoxia induced factor 1 alpha in experimental autoimmune encephalomyelitis. Eur J Immunol. 2019;49(12):2184–94.PubMedCrossRef
177.
Li L, et al. MiR-1-3p facilitates Th17 differentiation associating with multiple sclerosis via targeting ETS1. Eur Rev Med Pharmacol Sci. 2020;24(12):6881–92.PubMed
Metadaten
Titel
An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis
verfasst von
Marwa Kaisey
Ghazal Lashgari
Justyna Fert-Bober
Daniel Ontaneda
Andrew J. Solomon
Nancy L. Sicotte
Publikationsdatum
21.10.2022
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 10/2022
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-022-01227-1

Weitere Artikel der Ausgabe 10/2022

Current Neurology and Neuroscience Reports 10/2022 Zur Ausgabe

Headache (R.B. Halker Singh and J. VanderPluym, Section Editors)

Headache and Autonomic Dysfunction: a Review

Headache (R.B. Halker Singh and J. VanderPluym, Section Editors)

Vestibular Migraine

Sleep (M. Thorpy and M. Billiard, Section Editors)

Polysomnographic Predictors of Sleep, Motor, and Cognitive Dysfunction Progression in Parkinson’s Disease

Sleep (M. Thorpy and M. Billiard, Section Editors)

Longitudinal Studies of Sleep Disturbances in Parkinson’s Disease

Neurology of Systemic Diseases (J. Biller, Section Editor)

Neurologic Manifestations of Catastrophic Antiphospholipid Syndrome

Headache (R.B. Halker Singh and J. VanderPluym, Section Editors)

Outpatient Approach to Resistant and Refractory Migraine in Children and Adolescents: a Narrative Review

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus
Professorin Dr. Claudia Trenkwalder, Neurologin

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

19.04.2024 | AAN-Jahrestagung 2024 | Nachrichten

Hustenstiller lindert Agitation bei Alzheimer
weitere anzeigen

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise